Global Blood Therapeutics
NEWS
Global Blood Therapeutics was acquired by Pfizer in August 2022.
Global Blood Therapeutics, Inc. announced that it will present at the 2019 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 9, 2019, at 2:50 p.m. Eastern Time.
Global Blood Therapeutics, Inc. and the Sickle Cell Disease Association of America, Inc. announced that they will host the 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 10, 2019, at The Westin Washington, D.C. U.S. Representative Robin Kelly, chair of the Congressional Black Caucus Health Braintrust, will deliver the keynote address.
Global Blood Therapeutics, Inc. reported recent business progress and financial results for the second quarter ended June 30, 2019.
Global Blood Therapeutics, Inc. announced that it will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 13, 2019, at 1:55 p.m. Eastern Time.
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in the life science industry!
Global Blood Therapeutics, Inc. announced that on August 1, 2019, the compensation committee of GBT’s board of directors granted 14 new employees options to purchase an aggregate of 26,200 shares of the company’s common stock with a per share exercise price of $54.25 and restricted stock units for an aggregate of 69,450 shares of the company’s common stock.
Company Also Launches Disease Awareness Campaign to Raise Awareness Among Physicians About the Silent Damage Caused by Sickle Cell Disease
Global Blood Therapeutics, Inc. announced that on July 1, 2019, the compensation committee of GBT’s board of directors granted 13 new employees options to purchase an aggregate of 4,000 shares of the company’s common stock with a per share exercise price of $53.93 and restricted stock units for an aggregate of 31,700 shares of the company’s common stock.
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
JOBS
IN THE PRESS